Enclomiphene Citrate Cost in Utah 2026

Enclomiphene citrate has no FDA-approved commercial version, so every prescription filled in Utah in 2026 comes from a licensed 503A compounding pharmacy and is paid out of pocket. That single regulatory fact, not a manufacturer list price, is what shapes cost, insurance coverage, and access in this state. This page could not independently verify a current Utah-specific cash price from primary sources, so treat any single dollar figure you see elsewhere as a quote to confirm directly with the pharmacy, not a fixed market price.

What enclomiphene citrate is, and how it differs from clomiphene

The trans-isomer of clomiphene citrate, enclomiphene citrate is a selective estrogen receptor modulator. While clomiphene citrate carries FDA approval, that indication is restricted to ovulation induction in women and does not extend to male hypogonadism. Research on enclomiphene as a purified trans-isomer has focused on secondary (hypothalamic-pituitary) hypogonadism in men, where clinical use occurs through off-label prescribing or compounded formulations rather than through standalone FDA clearance. The FDA's public drug database (Drugs@FDA) provides current information on approved indications for clomiphene citrate.

A company (Repros Therapeutics) previously sought FDA approval for an enclomiphene product for male hypogonadism under the brand name Androxal. That product was not approved and is not commercially available. If the regulatory status matters to your decision, verify the current record yourself in FDA's Drugs@FDA search tool rather than relying on a specific application number reprinted secondhand, since those identifiers are easy to mistype or misattribute.

Mechanistically, enclomiphene blocks estrogen receptor feedback at the hypothalamus and pituitary, which is thought to increase LH and FSH output and, in turn, stimulate testicular testosterone production. This is why it is discussed as an alternative to testosterone replacement therapy (TRT) for men who want to preserve fertility and testicular function, since exogenous testosterone suppresses the same axis that enclomiphene is meant to stimulate.

Why there is no simple "Utah price" to quote

Because no enclomiphene product carries an FDA-approved NDA or NDC number, it cannot be priced the way a generic drug is priced through standard pharmacy benefit systems. Retail chain pharmacies generally do not stock it, since there is nothing commercially manufactured to stock. Every dose dispensed in Utah is compounded to order by a 503A pharmacy, and pricing is set independently by each compounding pharmacy and can change without notice.

That means a defensible cost answer for this page is a description of the pricing structure, not a specific number presented as current fact. What you should actually do before committing to treatment:

• Get a written quote directly from the specific 503A pharmacy your prescriber uses, dated the day you receive it.
• Ask whether the quote includes shipping, a compounding fee, and whether it changes with dose (12.5 mg versus 25 mg daily is a meaningfully different cost driver).
• Ask whether the pharmacy offers a multi-month subscription discount, since compounding pharmacies frequently structure pricing this way rather than as a flat monthly rate.
• Confirm the pharmacy is a Utah-licensed 503A facility, not an unlicensed international supplier, since safety and legal recourse both depend on that status.

Does Utah Medicaid cover enclomiphene citrate?

The general rule for state Medicaid pharmacy programs is that a drug typically needs an assigned National Drug Code (NDC) to be processed through the standard preferred drug list and rebate system (CMS Medicaid Drug Rebate Program). Because enclomiphene has no FDA-approved NDC for male hypogonadism, it is reasonable to expect that Utah Medicaid does not cover it as a standard formulary benefit, consistent with how most state Medicaid programs treat compounded, non-approved drugs generally.

This page does not have a verified, dated citation to Utah's specific Medicaid preferred drug list or a documented Utah exception-request approval rate, and those specifics should be confirmed directly with Utah Medicaid or your managed care plan before you assume coverage is or is not possible in your case. Prior authorization exception pathways exist in most state Medicaid programs, but approval for a compounded, non-FDA-approved product is not something this article can quantify reliably.

Does private insurance in Utah cover it?

Most ACA marketplace and employer-sponsored plans build formularies around FDA-approved, NDC-assigned drugs. General ACA rules on essential health benefits and formulary design are described by HHS (HealthCare.gov and the ACA), but individual insurer formularies for named Utah carriers change year to year and are not something this article can verify or attribute claims to without a current, insurer-specific source. If you have insurance, the reliable path is to call member services or check your plan's current Summary Plan Description for language about compounded drugs, fertility drugs, or off-label hormone therapy, rather than relying on which carriers are named in a general article.

A small number of self-funded employer plans nationally have added fertility-drug riders that occasionally extend to male fertility-preserving hormone therapy. Whether any specific Utah employer's plan does this is plan-specific and should be confirmed with your benefits administrator, not assumed from a general description.

Is compounded enclomiphene citrate legal to prescribe and dispense in Utah?

Yes. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to prepare medications for specific patients when a licensed prescriber issues an individualized prescription, provided the work meets USP standards for non-sterile compounding (FDA compounding overview; refer to USP's general chapters on compounding standards for full technical requirements). In Utah, a pharmacy preparing enclomiphene must maintain an active state pharmacy license and act on a patient-specific prescription from a qualified prescriber; batch preparation for inventory without such a prescription is not permitted.

If you want to confirm a specific pharmacy is properly licensed in Utah, verify directly with the Utah Division of Occupational and Professional Licensing rather than relying on a pharmacy's own claims about its licensure status.

Telehealth prescribing in Utah

Enclomiphene citrate is not a federally scheduled controlled substance. That matters because the Ryan Haight Online Pharmacy Consumer Protection Act, which restricts online prescribing of Schedule II-V controlled substances without a prior in-person exam, does not apply to it. This is a meaningful difference from testosterone itself, which is a Schedule III controlled substance and carries additional telehealth restrictions.

A typical telehealth pathway for enclomiphene involves lab confirmation of low testosterone with inappropriately low or normal LH/FSH (consistent with secondary rather than primary hypogonadism), a clinician visit to review those labs and rule out contraindications, and an electronic prescription sent to a 503A pharmacy. Telehealth is broadly relevant in a state with substantial rural geography, since specialist endocrinology or urology access outside the Wasatch Front can require significant travel; general federal resources on rural telehealth access are available through the CDC (CDC Rural Health and Telehealth), though this article does not have a verified, dated statistic on Utah broadband or telehealth uptake specifically.

What the clinical evidence actually shows, and its limits

Enclomiphene's clinical rationale rests on a small number of published trials and pharmacology reviews comparing it with testosterone therapy in men with secondary hypogonadism. In general terms, these studies have reported that enclomiphene can raise serum testosterone into a normal range while better preserving sperm concentration than exogenous testosterone, which is the basis for recommending it to men who want to maintain fertility. This is trial-level evidence from a limited number of relatively small studies, not a large real-world outcomes literature, and the specific numeric results (exact testosterone increases, exact sperm-preservation percentages) reported in secondary summaries should be checked against the original published trial before you rely on a precise figure, since this draft could not confirm those specific numbers against verified primary sources.

Clinical practice guideline bodies, including the Endocrine Society, generally favor agents that stimulate a man's own testosterone production (rather than exogenous testosterone) when fertility preservation is a treatment goal (Endocrine Society clinical practice guidelines on male hypogonadism). That guideline supports the category of treatment enclomiphene belongs to, but it does not specifically endorse enclomiphene by name as a first-line FDA-approved therapy, because no FDA-approved enclomiphene product currently exists.

The evidence boundary, stated plainly

Established: Enclomiphene is not FDA-approved as a standalone product for male hypogonadism; it is available only through compounding. Clomiphene citrate itself is FDA-approved, but only for female infertility. It is not a controlled substance, so Ryan Haight restrictions on controlled-substance telehealth prescribing do not apply to it.

Plausible but not settled at scale: Trial data suggest enclomiphene raises testosterone while better preserving semen parameters than exogenous testosterone in men with secondary hypogonadism, but the evidence base is a handful of smaller studies rather than a large, replicated outcomes literature, and long-term comparative safety data are limited.

Not established from the material available to this article: A specific, current, Utah-wide cash price; a specific Utah Medicaid coverage determination; specific named private insurer coverage rules for 2026; and a Utah-specific broadband or telehealth-uptake statistic. Any of these that you find quoted precisely elsewhere should be re-verified against a dated, primary source before you rely on it.

Monitoring, and why it adds to the real cost of treatment

Getting a prescription is not the end of the cost conversation. Ongoing hormone therapy of any kind, including enclomiphene, typically requires periodic lab monitoring: baseline testosterone, LH, FSH, and estradiol; hematocrit; and PSA in men over 40, given that testosterone-elevating therapy can affect all of these. The Endocrine Society's guideline on male hypogonadism describes monitoring hematocrit and PSA over time and adjusting dose based on testosterone response (Endocrine Society guideline); exact monitoring intervals should be set by your prescribing clinician based on your individual labs, not copied from a generic schedule.

Because estradiol can rise as testosterone rises (through aromatization), some men on enclomiphene are monitored for estradiol elevation and occasionally co-prescribed an aromatase inhibitor if levels run high. Whether that applies to you is an individualized clinical decision, not something a general cost article can determine.

Contraindications and when this is the wrong path

Enclomiphene is not appropriate for men with primary (testicular) hypogonadism, where LH and FSH are already elevated because the pituitary is already maximally stimulating testes that cannot respond; in that setting it will not raise testosterone. General contraindications discussed for clomiphene-class SERMs include active liver disease, untreated polycythemia, and active hormone-sensitive cancers, though your prescriber needs to confirm which apply to you specifically; this article cannot make an individualized eligibility or dosing determination. If you develop symptoms such as sudden vision changes, chest pain, calf swelling, or signs of a blood clot while on any testosterone-axis therapy, that is a reason for urgent medical evaluation, not a wait-and-see telehealth message.

Verification checklist: what is stable versus what you must re-check in 2026

Keep in mind the distinction between information that remains stable over time and details that may shift based on your individual prescription, insurance coverage, state regulations, or pharmacy policies.

Stable, federal or clinical (safe to treat as durable, but still worth a periodic spot-check):

• Enclomiphene has no FDA-approved NDA for male hypogonadism; confirm current status anytime at Drugs@FDA.
• Enclomiphene is not a federally scheduled controlled substance, so Ryan Haight restrictions on controlled-substance telehealth do not apply to it.
• 503A compounding requires a valid patient-specific prescription and a state pharmacy license; it is a federal framework, not a Utah-specific carve-out.
• Clinical guideline bodies generally prefer fertility-preserving agents over exogenous testosterone for men who want to remain fertile, a guideline-level (not FDA-label) recommendation.

Date-sensitive, plan- pharmacy- or state-specific (re-verify before you rely on it):

• The exact monthly cash price at any named Utah compounding pharmacy, as of today's date.
• Whether your specific Utah Medicaid managed care plan will approve any exception request for a compounded hormone therapy.
• Whether your specific employer or marketplace plan's current formulary excludes or covers compounded drugs, and under what prior-authorization criteria.
• Whether a given telehealth practice is licensed to prescribe in Utah and whether the compounding pharmacy it uses is currently in good standing with Utah's pharmacy board.
• Any discount, subscription, or loyalty pricing a specific pharmacy advertises, since compounding pharmacy pricing structures change without a public notice requirement.

If a source you are reading states a specific 2026 dollar figure, a specific Utah Medicaid approval rate, or a specific insurer's coverage rule without a dated citation you can click through and verify yourself, treat it as unverified until you confirm it directly with the payer or pharmacy.

Frequently asked questions

References

1. FDA Drugs@FDA database (drug approval search). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA, human drug compounding overview. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
3. CMS, Medicaid Drug Rebate Program. https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
4. HHS, About the Affordable Care Act. https://www.hhs.gov/healthcare/about-the-aca/index.html
5. Endocrine Society, Clinical Practice Guidelines on Male Hypogonadism. https://www.endocrine.org/clinical-practice-guidelines/male-hypogonadism
6. CDC, Rural Health and Telehealth. https://www.cdc.gov/ruralhealth/telehealth/index.html

This article is for general education and does not provide individualized diagnosis, dosing, or coverage determinations. Pricing, Medicaid policy, and insurer formularies change and should be confirmed directly with the relevant pharmacy, state agency, or payer before you make a treatment decision.